PN2034
Asset
Investigational insulin-sensitizing compound evaluated for improving glycemic control
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 2
- Trials
- 1
- Developer
Indications
1Type 2 diabetes
Phase 2, Completed, NCT00110851, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials2
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.